Executive Interviews

  1. 2018: The Year Of Biosimilar Commercialization Wins Or Woes?
    12/7/2017

    We reached out to eight experts from biosimilar companies and consulting firms to see which topics they’ve been watching closely throughout 2017 and how they expect these trends will evolve and challenge the industry in 2018.

  2. The Women Of Biopharma — Will They Gain Or Lose Ground In 2018?
    12/7/2017

    We hear from 11 women and one man in biopharma. Although we were not aiming for “balance” here — there are plenty of opposing opinions out there already — the sole gender-exception in this group supplies another valuable viewpoint…

  3. Are You Ready For The Future Of Biopharma Manufacturing?
    12/7/2017

    In last’s year’s manufacturing outlook we delved into biopharma’s manufacturing capacity crunch. While lack of manufacturing capacity remains a challenge for the industry, the future of biopharma manufacturing has never looked so bright, and there are a variety of reasons why.

  4. 7 Medical Device Leaders Talk About What’s Next For Their Industry
    12/7/2017

    Seven industry experts answer questions related to the med device funding climate, which device segment will be getting all of the attention in 2018, and upcoming M&A activity related to med devices.

  5. Virtual And Variable: Two Visions For Biopharma Outsourcing In 2018
    12/7/2017

    Deborah Dunsire, CEO of XTuit Pharmaceuticals; and Robert Discordia, executive director, global product development & supply procurement for Bristol-Myers Squibb discuss new approaches to external partnerships in pharma.

  6. Why All The Talk About Real-World Evidence?
    12/7/2017

    In 2017, real-world evidence (RWE) became the topic everyone wanted to discuss. Several executives I have spoken to recently believe it will continue to grow in importance as we move into 2018 and beyond. But why the sudden interest in RWE?

  7. Prophecy & Prognostication — A Charting Of Biopharma’s Future
    12/7/2017

    How do we best predict who or what might have a big impact on the biopharma industry in 2018? Although there are no guarantees with this kind of prognostication, we felt seeking the opinions of experienced top biopharma executives would be a good place to start.

  8. Are You Ready For The Future Of Biopharma Manufacturing?
    12/7/2017

    In last’s year’s manufacturing outlook we delved into biopharma’s manufacturing capacity crunch. While lack of manufacturing capacity remains a challenge for the industry, the future of biopharma manufacturing has never looked so bright, and there are a variety of reasons why.

  9. What Makes Roche’s Approach To Partnering Unusual
    11/8/2017

    Sophie Kornowski-Bonnet, Roche’s head of partnering, also serves on the company’s senior leadership team — a rarity among top biopharma companies. But that’s not the only unusual fact about Roche’s approach to partnering.

  10. From Startup To Acquisition By Lilly, And Everything In Between
    11/8/2017

    “Going to medical school, completing my residency, and pursuing my Ph.D. were a cake walk in comparison to being the CEO of a biotech,” says Daniel Skovronsky, M.D., Ph.D., who talks about his journey from working out of his car to selling his company for $300 million and then going to work for Lilly.